• Barrot H Lambdin, Peter J Davidson, Erica N Browne, Leslie W Suen, Lynn D Wenger, and Alex H Kral.
• RTI International, 2150 Shattuck Avenue, Suite 800, Berkeley, CA, 94704, USA. blambdin@rti.org.
• J Gen Intern Med. 2022 Nov 1; 37 (15): 385338603853-3860.

BackgroundSafe consumption sites (SCS) are an evidence-based intervention to prevent drug use-related harm. In late 2014, an organisation in an undisclosed location in the USA opened an unsanctioned SCS.ObjectiveTo evaluate whether use of the unsanctioned SCS affected medical outcomes.DesignA prospective cohort study.SettingNeighbourhoods surrounding the SCS.ParticipantsPeople who injected drugs were recruited and interviewed at baseline and 6 and 12 months from 2018 to 2020.InterventionPeople using the SCS could bring pre-obtained drugs to consume via injection, which were monitored by trained staff with naloxone.Main MeasuresAny overdose, number of non-fatal overdoses, skin and soft tissue infections, emergency department utilisation, number of emergency department visits, hospitalisation and number of nights spent in hospital.Key ResultsA total of 494 participants enrolled in the study; 59 (12%) used the SCS at least once. We used propensity score weighting to analyse the association between SCS utilisation and measures. People using the SCS were 27% (95% CI: 12-46%) less likely to visit the emergency department, had 54% (95% CI: 33-71%) fewer emergency department visits, were 32% (95% CI: 4-57%) less likely to be hospitalised, and spent 50% (95% CI: 1-85%) fewer nights in hospital. Though not significant, people using the SCS had a lower likelihood of overdosing and slightly higher likelihood of skin and soft tissue infections.ConclusionsOur findings support the use of SCS in the USA to reduce the growing burden of acute care service utilisation related to injection drug use.© 2021. The Author(s) under exclusive licence to Society of General Internal Medicine.

23 keywords...

hide…